Search for: "Sanofi Synthelabo"
Results 21 - 40
of 59
Sorted by Relevance
|
Sort by Date
2 Nov 2006, 9:50 pm
District Court for the Southern District of New York granted a preliminary injunction to Sanofi-Synthelabo and Bristol-Myers Squibb in their patent infringement case against Apotex. [read post]
23 Mar 2009, 7:34 am
After a detailed analysis of the facts, the court agreed with the district court's analysis that the disclosure of the chemical structure of the compound in the prior art was insufficient to either anticipate or render obvious a claim directed to one of the two enantiomers, given the difficulty and unpredictability in separating enantiomers and the unexpected division of the beneficial and harmful effects between the two enantiomers of this particular compound.More detail of… [read post]
14 Nov 2008, 2:08 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Plavix (Clopidogrel) - Canada: Selection patents upheld by Supreme Court: Apotex v Sanofi-Synthelabo Canada (Jeremy de Beer) (ipblog.ca)… [read post]
16 Dec 2008, 11:47 pm
Sanofi-Synthelabo v. [read post]
26 May 2009, 9:54 am
., IVAX Pharmaceuticals, Barr Laboratories, Aventis Pharmaceuticals, Aventis Behring, ZLB Behring, Sanofi-Synthelabo, Forest Laboratories, Forest Pharmaceuticals, Baxter Healthcare Corp. and Baxter International. [read post]
1 Jan 2008, 6:49 pm
Seagate – Petition from In re Seagate Bilski – Patent-Eligibility under § 101 Sanofi-Synthelabo – The Plavix Case Sang Su Lee II – Post-KSR Motivation Ferguson – Method of Marketing a Product Barnett – Internet-driven Method Hal Wegner’s list focuses on utility patent litigation. [read post]
15 Dec 2008, 5:34 am
Sanofi-Synthelabo v. [read post]
19 Dec 2008, 1:00 pm
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Plavix (Clopidogrel) – US: CAFC affirms nonobviousness of Plavix isomer patent: Sanofi-Synthelabo et al v Apotex (Patently-O) (Orange Book Blog) (Patent Prospector) (Law360) (Hal Wegner) (Patent Baristas) (Patent Docs) (Promote the Progress) (GenericsWeb) WHO meeting on pandemic influenza preparedness: last-minute… [read post]
11 Sep 2015, 3:00 am
Inc.; and Sanofi-Synthelabo Inc. [read post]
24 Dec 2008, 3:00 pm
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Classen v Biogen (not precedential): Federal Circuit applies Bilski to the life sciences (Holman's Biotech IP Blog) (Inventive Step) (Hal Wegner) (EFF) (Patently-O) (Patent Prospector) (The Fire of Genius) (Patent Baristas) (Managing Intellectual Property) (Patent Docs) (Spicy IP) General India: Investing farmers with IP… [read post]
18 Feb 2011, 11:47 am
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
21 Nov 2008, 11:36 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Plavix (Clopidogrel) – Canada: Supreme Court upholds selection patents: Apotex v Sanofi-Synthelabo Canada et al (Pharmacapsules @… [read post]
20 Aug 2012, 6:04 am
Popular bisphosphonate drugs and their manufacturers include: Actonel (Sanofi-Aventis/Procter & Gamble), Aredia (Novartis), Boniva (Roche Laboratories/Glaxo SmithKline), Didronel (OSG Norwich/Procter & Gamble), Fosamax (Merck), Skelid (Sanofi-Synthelabo), and Zometa (Novartis). [read post]
3 Nov 2011, 7:00 am
Popular bisphosphonate drugs and their manufacturers include: Actonel (Sanofi-Aventis/Procter & Gamble), Aredia (Novartis), Boniva (Roche Laboratories/Glaxo SmithKline), Didronel (OSG Norwich/Procter & Gamble), Fosamax (Merck), Skelid (Sanofi-Synthelabo), and Zometa (Novartis). [read post]
10 Apr 2015, 3:00 am
Services Inc., and Sanofi-Synthelabo, Inc., engaged in unfair and deceptive marketing practices relating to the efficacy of Plavix, an anti-clotting prescription drug. [read post]
28 Nov 2008, 12:49 pm
victories in fight for European BRCA patents (Holman's Biotech IP Blog) Europe: European Commission proposes strategy for dealing with rare diseases (Pharmacapsules @ Gowlings) US: Former House Ways and Means Economist claims 7-year data exclusive period is sufficient (Patent Docs) US: Medco predicts follow-on biologics regulatory pathway by 2011 (Patent Docs) US: Even after patent has expired, District Court has jurisdiction to set exclusivity date: In re Omeprazole Patent Litigation… [read post]
7 Nov 2008, 3:42 am
Sandoz, Inc (Patent Docs) (PATracer) Boniva (Ibandronic acid) – US: Hoffman La Roche files third patent infringement lawsuit against Orchid over generic Boniva (GenericsWeb) Carbatrol (Carbamazepine) – US: Federal Judge grants summary judgment of noninfringement to Corepharma in Carbatrol patent dispute with Shire Laboratories (Law360) Effexor (Venlafaxine) – US: Wyeth settles with fourth drug company, Anchen Pharmaceuticals, over generic Effexor (Law360) Fentora… [read post]
25 Jun 2007, 2:10 am
DISTRICT COURTSOUTHERN DISTRICT OF NEW YORKIntellectual Property
Sale of Generic Version of Plavix Blocked; Infringed Patent Not Proved Invalid or Unenforceable
Sanofi-Synthelabo v. [read post]
3 Feb 2010, 2:00 am
Barr Laboratories, Inc. and Mylan Pharma (Patent Docs) (Patently-O) Omnicef (Cefdinir) – US: CAFC on whether a product-by-process claim is infringed by an identical product made by different process: Abbott Labs v Sandoz (IP Frontline) Pertussis vaccines – UK: EWHC dismisses Medeva appeal against pertussis vaccines SPCs refusal (The SPC Blog) Plavix (Clopidogrel) – Canada: Adding some obvious flexibility: Apotex Inc v Sanofi-Synthelabo Canada Inc (IP Osgoode)… [read post]
25 Jan 2009, 2:36 pm
The last big pharmaceutical industry acquisition came in August 2004, when Paris-based Sanofi-Synthelabo acquired Aventis SA of Strasburg, France, for $64.4 billion to create Sanofi Aventis SA, France's largest drugmaker. [read post]
